Sheng Wu Gong Cheng Xue Bao. 2018 May 25;34(5):644-652. doi: 10.13345/j.cjb.170363.

[Process in menstrual blood-derived mesenchymal stem cells for treatment of central nervous system diseases].

[Article in Chinese; Abstract available in Chinese from the publisher]

Liu M¹, Cheng X¹, Li K¹, Xu M², Wu Y¹, Wang M¹, Zhang Q¹, Yan W¹, Luo C³, Zhao S¹.

Abstract

in English, Chinese

Stem cell research has become a frontier in the field of life sciences, and provides an ideal model for exploring developmental biology problems such as embryogenesis, histiocytosis, and gene expression regulation, as well as opens up new doors for clinical tissue defective and inheritance diseases. Among them, menstrual blood-derived stem cells (MenSCs) are characterized by wide source, multi-directional differentiation potential, low immune rejection characteristics. Thus, MenSCs can achieve individual treatment and have the most advantage of the clinical application. The central nervous system, including brain and spinal cord, is susceptible to injury. And lethality and morbidity of them tops the list of all types of trauma. Compared to peripheral nervous system, recovery of central nervous system after damage remains extremely hard. However, the treatment of stem cells, especially MenSCs, is expected to solve this problem. Therefore, biological characteristics of MenSCs and their treatment in the respect of central nervous system diseases have been reviewed at home and abroad in recent years, so as to provide reference for the treatment of central nervous system diseases.